|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Aquila_Biolabs
|
|
gptkbp:business_model
|
research-driven
|
|
gptkbp:can_lead_to
|
MD G1011
|
|
gptkbp:ceo
|
gptkb:Peter_Llewellyn-Davies
|
|
gptkbp:clinical_trial
|
gptkb:Europe
multiple
positive
Phase 1
innovative
Phase 3 trials
various demographics
secured
published in journals
cell-based therapies
|
|
gptkbp:collaborations
|
international
academic institutions
|
|
gptkbp:committee
|
experts
|
|
gptkbp:community_engagement
|
philanthropic initiatives
|
|
gptkbp:employees
|
approximately 100
|
|
gptkbp:financial_performance
|
published yearly
audited
|
|
gptkbp:focus
|
gptkb:vaccine
|
|
gptkbp:founded
|
gptkb:1997
|
|
gptkbp:grants
|
received
|
|
gptkbp:headquarters
|
gptkb:Martinsried,_Germany
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Medi Gene Inc.
|
|
gptkbp:invention
|
numerous
|
|
gptkbp:investment
|
active
institutional investors
biopharmaceuticals
R& D
|
|
gptkbp:language_of_instruction
|
multiple candidates
|
|
gptkbp:market
|
global
|
|
gptkbp:market_cap
|
€150 million (2021)
|
|
gptkbp:marketing_strategy
|
gptkb:collaboration
gptkb:video_game_series
|
|
gptkbp:partnership
|
gptkb:Eisai_Co.,_Ltd.
|
|
gptkbp:partnerships
|
pharmaceutical companies
biotech firms
|
|
gptkbp:products
|
ongoing
Tcell therapies
|
|
gptkbp:publishes
|
numerous
|
|
gptkbp:regulatory_compliance
|
gptkb:EMA
strict
|
|
gptkbp:research_and_development
|
high priority
|
|
gptkbp:research_areas
|
oncology
targeted therapies
various stages
|
|
gptkbp:research_focus
|
gptkb:healthcare_organization
immune-oncology
|
|
gptkbp:revenue
|
€20 million (2020)
|
|
gptkbp:social_responsibility
|
active
|
|
gptkbp:subsidiary
|
gptkb:Medigene_AG
|
|
gptkbp:sustainability
|
implemented
|
|
gptkbp:symbol
|
MD G1
|
|
gptkbp:traded_on
|
gptkb:Frankfurt_Stock_Exchange
|
|
gptkbp:type_of_care
|
high priority
|
|
gptkbp:website
|
www.medigene.com
|
|
gptkbp:bfsParent
|
gptkb:Medi_Gene_AG
|
|
gptkbp:bfsLayer
|
4
|